On
The SPARKLE study is the third and last of three clinical studies that form the Phase 3 program for Orviglance, the company’s orphan liver imaging agent.
© Modular Finance, source
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.25 SEK | -2.78% |
|
-43.24% | +55.79% |
06-17 | Transcript : Ascelia Pharma AB - Special Call | |
05-21 | Transcript : Ascelia Pharma AB, Q1 2024 Earnings Call, May 21, 2024 |
On
The SPARKLE study is the third and last of three clinical studies that form the Phase 3 program for Orviglance, the company’s orphan liver imaging agent.
© Modular Finance, source
1st Jan change | Capi. | |
---|---|---|
+55.79% | 17.23M | |
+26.33% | 46.56B | |
+45.38% | 41.67B | |
+0.03% | 41.16B | |
+32.94% | 32.4B | |
+20.78% | 28.18B | |
-6.35% | 28.1B | |
+48.97% | 14.52B | |
+48.08% | 13.74B | |
+3.27% | 12.17B |